VICTORIA, July 15, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF),
an industry leader in the discovery of novel, therapeutic
monoclonal antibodies, announces that it has entered into a new
antibody discovery collaboration with Entos Pharmaceuticals Inc.,
to develop a therapeutic candidate against an undisclosed,
immuno-oncology target, by leveraging ImmunoPrecise's proprietary B
cell Select™ platform.
ImmunoPrecise's well-established B cell
Select™ platform is capable of screening tens of
millions of cells, to identify a greater diversity of antibodies,
with very little manipulation. This proprietary platform is species
and tissue independent, allowing for the generation of antibodies
from samples not possible using other methods. The B cell
Select™ platform takes advantage of the diversity of
the animal's immune repertoire, and allows for screening of any
protein class, complex therapeutic targets, post-translational
modifications, and small molecules.
"Our B cell Select™ platform has a proven track record of
discovering large panels of high-affinity antibodies against a
broad range of antibody targets, including difficult membrane
proteins. Our North American B cell laboratory boasts over one
decade of experience with a 94% success rate. This is, in part, why
we are very confident in these collaborations, and continue to
field requests from such reputable groups," said Dr. Jennifer Bath, IPA President and CEO. "We are
pleased that Entos Pharmaceuticals Inc., a global leader in
next generation nucleic acid-based therapies, considers us to be a
trusted partner in antibody discovery."
"The team at Entos is committed to developing breakthrough
medicines to address pressing clinical unmet needs," said Dr.
John Lewis, CEO of Entos. "We have
been extremely impressed with IPA's B cell Select™ platform,
which provides an ideal approach to develop therapeutic
candidates."
Andy Nixon stepping down from
ImmunoPrecise's Board.
The Company also announces that board director Andy
Nixon has stepped down from his duties due to an arisen
conflict of interest.
ImmunoPrecise's Chair, James Kuo, stated they
"regretfully" accepted Andy's resignation "We will miss Andy's
contribution on the ImmunoPrecise board. He is a highly qualified
Director and we wish him every success in the future", Kuo
said.
Erratum
In May 30th news Release Extension
of Warrant Expiry Dates, the actual placement date should've read
June 18, 2018.
"The Company also announces that it will apply to the TSX
Venture Exchange to extend the expiry date of 875,000 share
purchase warrants issued in a private placement financing on
June 18, 2018 (see news release dated
June 19, 2018). The share
purchase warrants are exercisable at a price of $1.00 per share and the expiry date is being
extended from June 18, 2019 to
June 18, 2020. The extension of
the expiry date is subject to the acceptance of the TSX Venture
Exchange."
About Entos Pharmaceuticals
Entos Pharmaceuticals is focused on the development of next
generation nucleic acid-based therapies using their proprietary
Fusogenix drug delivery system. Fusogenix uses a novel mechanism of
action to deliver molecules, intact and unmodified, directly into
the cytosol of target cells. The technology is applicable to a wide
range of therapeutic types including gene therapy, mRNA, miRNA,
RNAi and CRISPR.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
company focused on the next generation of antibody discovery, to
deliver the most therapeutically-relevant antibodies, in a shorter
period of time, with the highest probability of succeeding to
clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory
facilities located in Victoria, British Columbia and Oss, the Netherlands, in collaboration with it's
wholly owned subsidiary U-Protein Express B.V., in Utrecht,
the Netherlands. The Company
operates globally to offer a continuum of superior antibody
services, from target analysis to pre-clinical studies.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.